| scholarly article | Q13442814 |
| P2093 | author name string | B Leeb | |
| J S Smolen | |||
| M Feldmann | |||
| J D Macfarlane | |||
| J R Kalden | |||
| R N Maini | |||
| F C Breedveld | |||
| C Antoni | |||
| M J Elliott | |||
| H Bijl | |||
| P2860 | cites work | The american rheumatism association 1987 revised criteria for the classification of rheumatoid arthritis | Q27860872 |
| Mice deficient for the 55 kd tumor necrosis factor receptor are resistant to endotoxic shock, yet succumb to L. monocytogenes infection | Q28509078 | ||
| DAB486IL-2 fusion toxin in refractory rheumatoid arthritis | Q33492932 | ||
| Construction and initial characterization of a mouse-human chimeric anti-TNF antibody | Q34060890 | ||
| Chronic exposure to tumor necrosis factor (TNF) in vitro impairs the activation of T cells through the T cell receptor/CD3 complex; reversal in vivo by anti-TNF antibodies in patients with rheumatoid arthritis | Q34229344 | ||
| Involvement of endogenous tumor necrosis factor alpha and transforming growth factor beta during induction of collagen type II arthritis in mice | Q37147228 | ||
| Anti-tumor necrosis factor ameliorates joint disease in murine collagen-induced arthritis | Q37253521 | ||
| Clinical management of rheumatoid arthritis | Q40708035 | ||
| New directions for biological therapy in rheumatoid arthritis | Q40760356 | ||
| The American College of Rheumatology preliminary core set of disease activity measures for rheumatoid arthritis clinical trials. The Committee on Outcome Measures in Rheumatoid Arthritis Clinical Trials | Q40914450 | ||
| Repeated therapy with monoclonal antibody to tumour necrosis factor alpha (cA2) in patients with rheumatoid arthritis | Q42694138 | ||
| Inhibitory effect of TNF alpha antibodies on synovial cell interleukin-1 production in rheumatoid arthritis | Q44064388 | ||
| Treatment of rheumatoid arthritis with chimeric monoclonal antibodies to tumor necrosis factor α | Q56813295 | ||
| Analysis of improvement in individual rheumatoid arthritis patients treated with disease-modifying antirheumatic drugs, based on the findings in patients treated with placebo. The Cooperative Systematic Studies of Rheumatic Diseases Group | Q67285449 | ||
| Expression of granulocyte-macrophage colony-stimulating factor in rheumatoid arthritis: regulation by tumor necrosis factor-alpha | Q68007091 | ||
| Tumour-necrosis-factor antibody treatment in Crohn's disease | Q72225713 | ||
| Therapeutic criteria in rheumatoid arthritis | Q80386526 | ||
| P433 | issue | 8930 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | antibody | Q79460 |
| placebo | Q269829 | ||
| monoclonal antibody | Q422248 | ||
| rheumatoid arthritis | Q187255 | ||
| TNF | Q18032037 | ||
| P304 | page(s) | 1105-10 | |
| P577 | publication date | 1994-10-22 | |
| P1433 | published in | The Lancet | Q939416 |
| P1476 | title | Randomised double-blind comparison of chimeric monoclonal antibody to tumour necrosis factor alpha (cA2) versus placebo in rheumatoid arthritis | |
| P478 | volume | 344 |
| Q61971528 | 11 Beta-hydroxysteroid dehydrogenase type 1 regulates synovitis, joint destruction, and systemic bone loss in chronic polyarthritis |
| Q35126551 | 15-deoxy-delta(12,14)-PGJ(2) induces synoviocyte apoptosis and suppresses adjuvant-induced arthritis in rats |
| Q71576582 | 3rd International Symposium on the Immunotherapy of the Rheumatic Diseases. 10-14 May 1995, Cyprus. Abstracts |
| Q91938966 | A Combined Transcriptomic and Genomic Analysis Identifies a Gene Signature Associated With the Response to Anti-TNF Therapy in Rheumatoid Arthritis |
| Q39507396 | A Limulus antilipopolysaccharide factor-derived peptide exhibits a new immunological activity with potential applicability in infectious diseases |
| Q26801912 | A Neurologist's Guide to TNF Biology and to the Principles behind the Therapeutic Removal of Excess TNF in Disease |
| Q51715223 | A case of planned pregnancy with an interruption in infliximab administration in a 27-year-old female patient with rheumatoid-factor-positive polyarthritis juvenile idiopathic arthritis which improved after restarting infliximab and methotrexate. |
| Q33370462 | A case report of tumor necrosis factor-alpha antibody-induced thrombocytopenia associated with emerging IgM anticardiolipin antibody in patients with scleroderma overlap/rheumatoid arthritis |
| Q28188829 | A clinical and economic review of disease-modifying antirheumatic drugs |
| Q37378732 | A clinical trial and extension study of infliximab in Korean patients with active rheumatoid arthritis despite methotrexate treatment. |
| Q73274030 | A coculture model of synoviocytes and bone for the evaluation of potential arthritis therapies |
| Q50688343 | A cost-cost study comparing etanercept with infliximab in rheumatoid arthritis. |
| Q93052453 | A fascinating story of the discovery & development of biologicals for use in clinical medicine |
| Q45889035 | A gene therapy approach to treatment of autoimmune disease |
| Q33354118 | A large-scale rheumatoid arthritis genetic study identifies association at chromosome 9q33.2. |
| Q36477515 | A longitudinal genome-wide association study of anti-tumor necrosis factor response among Japanese patients with rheumatoid arthritis |
| Q44469108 | A lupus-like syndrome associated with infliximab therapy |
| Q73959588 | A metalloprotease-inhibitor reduces pain associated behavior in mice with experimental neuropathy |
| Q31090628 | A novel method predicting clinical response using only background clinical data in RA patients before treatment with infliximab |
| Q44781566 | A pilot study of etanercept in the treatment of primary sclerosing cholangitis |
| Q43184375 | A proof-of-concept and drug-drug interaction study of pamapimod, a novel p38 MAP kinase inhibitor, with methotrexate in patients with rheumatoid arthritis |
| Q33158097 | A rare case of supraventricular tachycardia induced by Infliximab: a case report |
| Q34998962 | A single functional group substitution in c5a breaks B cell and T cell tolerance and protects against experimental arthritis |
| Q43957787 | A small molecule ubiquitination inhibitor blocks NF-kappa B-dependent cytokine expression in cells and rats |
| Q41876223 | A survey of inclusion of the time element when reporting adverse effects in randomised controlled trials of cyclo-oxygenase-2 and tumour necrosis factor alpha inhibitors |
| Q37654401 | ADAM19: A Novel Target for Metabolic Syndrome in Humans and Mice. |
| Q34822331 | Abrogation of antibody-induced arthritis in mice by a self-activating viridin prodrug and association with impaired neutrophil and endothelial cell function |
| Q34939962 | Accelerated pathological and clinical nephritis in systemic lupus erythematosus-prone New Zealand Mixed 2328 mice doubly deficient in TNF receptor 1 and TNF receptor 2 via a Th17-associated pathway |
| Q33782402 | Access to disease modifying treatments for rheumatoid arthritis patients |
| Q89051282 | Activated human Foxp3+ regulatory T cells produce membrane-bound TNF |
| Q41893585 | Activated macrophages are essential in a murine model for T cell-mediated chronic psoriasiform skin inflammation |
| Q44520957 | Activation of FoxO3a/Bim axis in patients with Primary Biliary Cirrhosis |
| Q24675105 | Adalimumab (a fully human anti-tumour necrosis factor alpha monoclonal antibody) in the treatment of active rheumatoid arthritis: the initial results of five trials |
| Q35093636 | Adalimumab - a new TNF-alpha antibody for treatment of inflammatory joint disease |
| Q34896439 | Adalimumab clinical efficacy is associated with rheumatoid factor and anti-cyclic citrullinated peptide antibody titer reduction: a one-year prospective study |
| Q36708319 | Adalimumab for rheumatoid arthritis |
| Q38192659 | Adalimumab in the treatment of rheumatoid arthritis |
| Q34071292 | Adenoviral transgene delivery provides an approach to identifying important molecular processes in inflammation: evidence for heterogenecity in the requirement for NFkappaB in tumour necrosis factor production |
| Q35030921 | Advances in the management of psoriasis: monoclonal antibody therapies |
| Q34779732 | Affect of serum leptin on nutritional status in renal disease |
| Q71104634 | Allele-specific quantification of TNFA transcripts in rheumatoid arthritis |
| Q45868500 | Amelioration of established collagen induced arthritis by systemic IL-10 gene delivery |
| Q33511764 | An eight-gene blood expression profile predicts the response to infliximab in rheumatoid arthritis. |
| Q36271120 | Analysing the effect of novel therapies on cytokine expression in experimental arthritis |
| Q30834746 | Analysis of immune system gene expression in small rheumatoid arthritis biopsies using a combination of subtractive hybridization and high-density cDNA arrays |
| Q64075128 | Anti-TNF Therapy in Spondyloarthritis and Related Diseases, Impact on the Immune System and Prediction of Treatment Responses |
| Q34216181 | Anti-TNF agents for rheumatoid arthritis |
| Q37170834 | Anti-TNF immunotherapy reduces CD8+ T cell-mediated antimicrobial activity against Mycobacterium tuberculosis in humans |
| Q34450313 | Anti-TNF therapy for rheumatoid arthritis and other inflammatory diseases |
| Q48823077 | Anti-TNF therapy from the bench to the clinic: a paradigm of translational research. |
| Q26997311 | Anti-TNF therapy: past, present and future |
| Q36377196 | Anti-TNF-alpha agents in the treatment of psoriatic arthritis |
| Q40963908 | Anti-cytokine therapy in rheumatoid arthritis |
| Q57351157 | Anti-inflammatory effects of a new tumour necrosis factor-alpha (TNF-alpha) inhibitor (CNI-1493) in collagen-induced arthritis (CIA) in rats |
| Q34071253 | Anti-interleukin 6 receptor antibody treatment in rheumatic disease |
| Q40845933 | Anti-tumor necrosis factor-alpha monoclonal antibody therapy for rheumatoid arthritis |
| Q40617558 | Anti-tumor necrosis factor-alpha therapy with infliximab as an alternative to corticosteroids in the treatment of human leukocyte antigen B27-associated acute anterior uveitis |
| Q45402264 | Anti-tumour necrosis factor agents reduce non-steroidal anti-inflammatory drug-induced small bowel injury in rheumatoid arthritis patients |
| Q33782344 | Anti-tumour necrosis factor specific antibody (infliximab) treatment provides insights into the pathophysiology of rheumatoid arthritis |
| Q40312662 | Anti-tumour necrosis factor-alpha therapy over conventional therapy improves endothelial function in adults with rheumatoid arthritis. |
| Q37505420 | Antibody engineering to develop new antirheumatic therapies |
| Q73502964 | Anticytokine Therapy in Rheumatoid Arthritis |
| Q41926993 | Antimalarial drugs inhibit phospholipase A2 activation and induction of interleukin 1beta and tumor necrosis factor alpha in macrophages: implications for their mode of action in rheumatoid arthritis |
| Q35967177 | Antimetabolites in the treatment of arthritis: current status of the use of antimetabolites |
| Q33944344 | Antiphospholipid antibodies during 6-month treatment with infliximab: a preliminary report. |
| Q33641577 | Antitumor necrosis factor therapy for inflammatory bowel disease: a review of agents, pharmacology, clinical results, and safety |
| Q57674399 | Apoptosis of biliary epithelial cells in primary biliary cirrhosis and primary sclerosing cholangitis |
| Q34476049 | Appropriate infliximab infusion dosage and monitoring: results of a panel meeting of rheumatologists, dermatologists and gastroenterologists |
| Q41664176 | Are bacterial exotoxins cytokine network regulators? |
| Q38248092 | Are sample sizes of randomized clinical trials in rheumatoid arthritis too large? |
| Q95277418 | Association Between Tumor Necrosis Factor Inhibitor Exposure and Inflammatory Central Nervous System Events |
| Q50108689 | Association between tumor necrosis factor receptor II and familial, but not sporadic, rheumatoid arthritis: evidence for genetic heterogeneity |
| Q35551774 | Autoantibodies against interleukin 1alpha in rheumatoid arthritis: association with long term radiographic outcome. |
| Q53845804 | Autoantibody profile during short-term infliximab treatment for Crohn's disease: a prospective cohort study. |
| Q33601679 | Autoantibody-dependent and autoantibody-independent roles for B cells in systemic lupus erythematosus: past, present, and future |
| Q47771380 | Autoimmunity associated with anti-tumor necrosis factor alpha treatment in Crohn's disease: a prospective cohort study |
| Q71719521 | Autologous blood stem cell transplantation for autoimmune diseases |
| Q43589230 | Baseline TNFα operational capacity in fetal and maternal circulation prior to the onset of labor: "tuned for different purposes". |
| Q40467512 | Beneficial effects of tumour necrosis factor-alpha (TNF-α) blockade in rheumatoid arthritis (RA) |
| Q35031727 | Benefit-risk assessment of infliximab in the treatment of rheumatoid arthritis |
| Q40845939 | Biologic agents and immunotherapy in rheumatoid arthritis. Progress and perspective |
| Q41201773 | Biologic agents for the treatment of rheumatoid arthritis |
| Q26471538 | Biologic interventions for fatigue in rheumatoid arthritis |
| Q34108783 | Biologic therapies in rheumatoid arthritis |
| Q36849136 | Biologic therapy in the management of extraintestinal manifestations of inflammatory bowel disease |
| Q37087438 | Biologic treatments for systemic rheumatic diseases |
| Q47710265 | Biological Therapies for Eosinophilic Esophagitis: Where Do We Stand? |
| Q35807230 | Biological agents for rheumatoid arthritis: targeting both physical function and structural damage |
| Q34074934 | Biological agents: a novel approach to the therapy of rheumatoid arthritis |
| Q77627751 | Biological insights from clinical trials with anti-TNF therapy |
| Q37290665 | Biological therapies for the treatment of juvenile idiopathic arthritis: Lessons from the adult and pediatric experiences |
| Q40436519 | Biological therapies: a novel approach to the treatment of autoimmune disease |
| Q43251968 | Blockade of tumor necrosis factor in collagen-induced arthritis reveals a novel immunoregulatory pathway for Th1 and Th17 cells |
| Q40963916 | Bone marrow transplantation in auto-immune disease. |
| Q86032830 | Bone status in adults with early-onset juvenile idiopathic arthritis following 1-year anti-TNFα therapy and discontinuation of glucocorticoids |
| Q33782282 | Building towards a consensus for the use of tumour necrosis factor blocking agents |
| Q28143405 | Butyrate inhibits inflammatory responses through NFkappaB inhibition: implications for Crohn's disease |
| Q35126948 | C-C chemokine-encoding DNA vaccines enhance breakdown of tolerance to their gene products and treat ongoing adjuvant arthritis |
| Q24804352 | CD44 in rheumatoid arthritis |
| Q36958322 | CD44 involvement in autoimmune inflammations: the lesson to be learned from CD44-targeting by antibody or from knockout mice |
| Q28254498 | CDP-870 (certolizumab) in rheumatoid arthritis |
| Q35895488 | Caprine arthritis encephalitis virus dysregulates the expression of cytokines in macrophages. |
| Q34071308 | Cartilage destruction and bone erosion in arthritis: the role of tumour necrosis factor alpha |
| Q37895016 | Changes in patient characteristics in anti-tumour necrosis factor clinical trials for rheumatoid arthritis: results of an analysis of the literature over the past 16 years |
| Q82028773 | Chapter 17 Cytokines and pain |
| Q90150601 | Characterization of Novel Fragment Antibodies Against TNF-alpha Isolated Using Phage Display Technique |
| Q44144614 | Chemical stabilities and biological activities of thalidomide and its N-alkyl analogs. |
| Q30839917 | Chemically modified ribozyme targeting TNF-alpha mRNA regulates TNF-alpha and IL-6 synthesis in synovial fibroblasts of patients with rheumatoid arthritis |
| Q41946037 | Chloroquine inhibits production of TNF-alpha, IL-1beta and IL-6 from lipopolysaccharide-stimulated human monocytes/macrophages by different modes |
| Q41630705 | Chronic inflammation in older people: recognition, consequences, and potential intervention. |
| Q36377176 | Chronic tumor necrosis factor alters T cell responses by attenuating T cell receptor signaling |
| Q24799187 | Circulating tumour necrosis factor-alpha bioactivity in rheumatoid arthritis patients treated with infliximab: link to clinical response |
| Q38589168 | Clinical and Preclinical Use of LOX-1-Specific Antibodies in Diagnostics and Therapeutics |
| Q33809743 | Clinical experience with soluble TNF p75 receptor in rheumatoid arthritis |
| Q37157407 | Clinical investigation in highly disease-affected rheumatoid arthritis patients in Japan with adalimumab applying standard and general evaluation: the CHANGE study |
| Q39227095 | Clinical pharmacology and therapeutic potential of monoclonal antibody treatment in rheumatoid arthritis |
| Q37055162 | Clinical presentation, pathogenesis, diagnosis, and treatment of epidermolysis bullosa acquisita |
| Q34543634 | Clinically useful monoclonal antibodies in treatment |
| Q34447437 | Collagen II antibody-induced arthritis in Tg1278TNFko mice: optimization of a novel model to assess treatments targeting human TNFα in rheumatoid arthritis |
| Q40524018 | Colonic sarcoidosis, infliximab, and tuberculosis: a cautionary tale |
| Q34309751 | Combination therapy for autoimmune diseases: the rheumatoid arthritis model |
| Q77627740 | Combination therapy in mice: what can we learn that may be useful for understanding rheumatoid arthritis? |
| Q34276019 | Combinations of conventional disease-modifying antirheumatic drugs |
| Q90177398 | Combined Experimental Approach and Finite Element Modeling of Small Molecule Transport Through Joint Synovium to Measure Effective Diffusivity |
| Q36677277 | Consensus statement on blocking the effects of interleukin-6 and in particular by interleukin-6 receptor inhibition in rheumatoid arthritis and other inflammatory conditions |
| Q33954663 | Consensus statement on the initiation and continuation of tumour necrosis factor blocking therapies in rheumatoid arthritis |
| Q35873708 | Considerations with the use of biological therapy in the treatment of rheumatoid arthritis |
| Q34427742 | Criteria for TNF-targeted therapy in rheumatoid arthritis: estimates of the number of patients potentially eligible |
| Q35540944 | Current Status of Tumor Necrosis Factor Inhibition Strategies in the Treatment of Vasculitis |
| Q34479140 | Current and emerging therapies for rheumatoid arthritis, with a focus on infliximab: clinical impact on joint damage and cost of care in canada |
| Q35823636 | Current and new antitumor necrosis factor agents in perspective |
| Q24804893 | Current perspectives on synovitis |
| Q35210206 | Current treatment of psoriatic arthritis |
| Q34240751 | Current use of biologicals for the treatment of spondyloarthropathies |
| Q35617573 | Cytokine disturbances in systemic lupus erythematosus |
| Q41209346 | Cytokine inhibitors in autoimmune disease |
| Q38017731 | Cytokine networks in Pemphigus vulgaris: An integrated viewpoint |
| Q73174874 | Cytokine stimulation of T lymphocytes regulates their capacity to induce monocyte production of tumor necrosis factor-alpha, but not interleukin-10: possible relevance to pathophysiology of rheumatoid arthritis |
| Q72276503 | Cytokine therapeutics |
| Q71547893 | Cytokine therapy in rheumatoid arthritis |
| Q41745135 | Cytokine-directed therapies in multiple sclerosis and experimental autoimmune encephalomyelitis |
| Q40409319 | Cytokine-processing enzymes. Stopping the cuts |
| Q36038708 | Cytokines and alcoholic liver disease. |
| Q41429814 | Cytokines and cell regulation. |
| Q22306446 | Cytokines and cytokine profiles in human autoimmune diseases and animal models of autoimmunity |
| Q35174889 | Cytokines and immunopathogenesis of intraocular posterior segment inflammation |
| Q41312485 | Cytokines in autoimmunity |
| Q38244567 | Cytokines in immune-mediated inflammatory myopathies: cellular sources, multiple actions and therapeutic implications. |
| Q43204450 | Cytokines in inflammatory bowel disease |
| Q33974537 | Cytokines in rheumatoid arthritis: trials and tribulations |
| Q38459083 | Cytokines: Names and Numbers You Should Care About |
| Q38335184 | DNA microarray allows molecular profiling of rheumatoid arthritis and identification of pathophysiological targets. |
| Q36364193 | Defining therapeutic targets by using adenovirus: blocking NF-kappaB inhibits both inflammatory and destructive mechanisms in rheumatoid synovium but spares anti-inflammatory mediators |
| Q78309903 | Demographic and clinical parameters influencing the short-term outcome of anti-tumor necrosis factor (infliximab) treatment in Crohn's disease |
| Q34395739 | Demyelinating and neurologic events reported in association with tumor necrosis factor alpha antagonism: by what mechanisms could tumor necrosis factor alpha antagonists improve rheumatoid arthritis but exacerbate multiple sclerosis? |
| Q30667754 | Demyelination occurring during anti-tumor necrosis factor alpha therapy for inflammatory arthritides |
| Q43048724 | Depletion of synovial macrophages in rheumatoid arthritis by an anti-FcgammaRI-calicheamicin immunoconjugate |
| Q59659107 | Desarrollo y aplicación del Modelo Payback para la evaluación del impacto socioeconómico de la investigación en salud |
| Q99579418 | Designing custom CRISPR libraries for hypothesis-driven drug target discovery |
| Q59192710 | Detection of experimental infections with 99mTc-labeled monoclonal antibodies against TNF-α and interleukin-8 |
| Q74187188 | Development of anti-TNF therapy for rheumatoid arthritis |
| Q37207010 | Developments in the clinical understanding of rheumatoid arthritis |
| Q35690977 | Dicer-substrate siRNA inhibits tumor necrosis factor alpha secretion in Kupffer cells in vitro: in vivo targeting of Kupffer cells by siRNA-liposomes |
| Q40878936 | Dietary n-3 fatty acids and therapy for rheumatoid arthritis |
| Q93154989 | Different Original and Biosimilar TNF Inhibitors Similarly Reduce Joint Destruction in Rheumatoid Arthritis-A Network Meta-Analysis of 36 Randomized Controlled Trials |
| Q35549213 | Differential Th1/Th2 cytokine patterns in chronic arthritis: interferon gamma is highly expressed in synovium of rheumatoid arthritis compared with seronegative spondyloarthropathies |
| Q73065149 | Differential regulation of rheumatoid synovial cell interleukin-12 production by tumor necrosis factor alpha and CD40 signals |
| Q33548150 | Differing effect of systemic anti psoriasis therapies on platelet physiology--a case report and review of literature |
| Q36477567 | Direct adenovirus-mediated gene transfer of interleukin 1 and tumor necrosis factor alpha soluble receptors to rabbit knees with experimental arthritis has local and distal anti-arthritic effects |
| Q34540317 | Discovery of TNF-alpha as a therapeutic target in rheumatoid arthritis: preclinical and clinical studies |
| Q33708846 | Do anti-TNF agents have equal efficacy in patients with rheumatoid arthritis? |
| Q50870127 | Does sex of rheumatoid arthritis patients matter? |
| Q33590773 | Dose REduction strategy of subcutaneous TNF inhibitors in rheumatoid arthritis: design of a pragmatic randomised non inferiority trial, the DRESS study |
| Q98465635 | Drug Tolerant Anti-drug Antibody Assay for Infliximab Treatment in Clinical Practice Identifies Positive Cases Earlier |
| Q50083992 | Drug safety and immunogenicity of tumour necrosis factor inhibitors: the story so far. |
| Q40903047 | Drug treatment of rheumatic diseases in the 1990s. Achievements and future developments |
| Q77627769 | Drug-combination therapy of rheumatoid arthritis |
| Q37868002 | Drug-induced lupus erythematosus: incidence, management and prevention |
| Q77360241 | Dynamic changes in cytokine levels in serum and synovial fluid following filtration leukocytapheresis therapy in patients with rheumatoid arthritis |
| Q35746217 | Dynamics of early synovial cytokine expression in rodent collagen-induced arthritis : a therapeutic study using a macrophage-deactivating compound. |
| Q92737266 | Early phase and adaptive design clinical trials in rheumatoid arthritis: a systematic review of early phase trials |
| Q36563395 | Early rheumatoid arthritis: pitfalls in diagnosis and review of recent clinical trials |
| Q33578559 | Early rheumatoid arthritis: time to aim for remission? |
| Q40535432 | Ectodomain shedding of the glycoprotein GP of Ebola virus |
| Q34550173 | Effect of pregnancy and obstructive jaundice on inflammatory diseases: the work of P S Hench revisited |
| Q44951728 | Effect of therapeutic integrin (CD11a) blockade with efalizumab on immune responses to model antigens in humans: results of a randomized, single blind study |
| Q54779051 | Effects and mechanisms of glucosides of chaenomeles speciosa on collagen-induced arthritis in rats |
| Q39253899 | Effects of 18β-Glycyrrhetinic acid in hTNFtg mice - a model of rheumatoid arthritis |
| Q53654871 | Effects of TNF-alpha injected intracisternally on the nociceptive jaw-opening reflex and orofacial formalin test in freely moving rats. |
| Q41133430 | Effects of antirheumatic agents on cytokines |
| Q35953547 | Effects of intra-articular corticosteroids and anti-TNF therapy on neutrophil activation in rheumatoid arthritis |
| Q35550664 | Effects of treatment with a fully human anti-tumour necrosis factor alpha monoclonal antibody on the local and systemic homeostasis of interleukin 1 and TNFalpha in patients with rheumatoid arthritis. |
| Q35554130 | Efficacy and safety of adalimumab as monotherapy in patients with rheumatoid arthritis for whom previous disease modifying antirheumatic drug treatment has failed |
| Q34768442 | Efficacy and tolerability of tocilizumab in rheumatoid arthritis patients seen in daily clinical practice in Japan: results from a retrospective study (REACTION study). |
| Q40811142 | Efficacy of adenoviral TNF alpha antisense is enhanced by a macrophage specific promoter. |
| Q42603607 | Efficacy, pharmacokinetic, and safety assessment of adalimumab, a fully human anti-tumor necrosis factor-alpha monoclonal antibody, in adults with rheumatoid arthritis receiving concomitant methotrexate: a pilot study |
| Q36062038 | Efficacy, tolerability and cost effectiveness of disease-modifying antirheumatic drugs and biologic agents in rheumatoid arthritis |
| Q36172262 | Efficient adenoviral infection with IkappaB alpha reveals that macrophage tumor necrosis factor alpha production in rheumatoid arthritis is NF-kappaB dependent |
| Q30933288 | Efficient generation of respiratory syncytial virus (RSV)-neutralizing human MoAbs via human peripheral blood lymphocyte (hu-PBL)-SCID mice and scFv phage display libraries |
| Q88055955 | Eleutheroside E ameliorates arthritis severity in collagen-induced arthritis mice model by suppressing inflammatory cytokine release |
| Q34731307 | Emerging role of anti-tumor necrosis factor therapy in rheumatic diseases |
| Q41525992 | Emerging treatments for rheumatoid arthritis |
| Q36580095 | Endogenous TLR ligands and autoimmunity |
| Q24793680 | Endothelial cell phenotypes in the rheumatoid synovium: activated, angiogenic, apoptotic and leaky |
| Q42099566 | Enhanced gene transfer to arthritic joints using adeno-associated virus type 5: implications for intra-articular gene therapy |
| Q40980471 | Enhancement of the surface expression of tumor necrosis factor alpha (TNFalpha) but not the p55 TNFalpha receptor in the THP-1 monocytic cell line by matrix metalloprotease inhibitors |
| Q42704864 | Escherichia coli Nissle 1917 distinctively modulates T-cell cycling and expansion via toll-like receptor 2 signaling |
| Q37316594 | Evidence that cytokines play a role in rheumatoid arthritis |
| Q43873302 | Evidence that rheumatoid arthritis synovial T cells are similar to cytokine-activated T cells: involvement of phosphatidylinositol 3-kinase and nuclear factor kappaB pathways in tumor necrosis factor alpha production in rheumatoid arthritis |
| Q29618020 | Evolving concepts of rheumatoid arthritis |
| Q28075692 | Excess cerebral TNF causing glutamate excitotoxicity rationalizes treatment of neurodegenerative diseases and neurogenic pain by anti-TNF agents |
| Q71018485 | Expression of interferon-gamma (IFN-gamma), IL-10, IL-12 and transforming growth factor-beta (TGF-beta) mRNA in synovial fluid cells from patients in the early and late phases of rheumatoid arthritis (RA) |
| Q73268780 | Expression of interleukin 6 in synovial tissues in patients with internal derangement of the temporomandibular joint |
| Q47915123 | Fatal staphylococcal sepsis in Crohn's disease after infliximab |
| Q90590786 | Finding the vulnerable checkpoint |
| Q43704009 | Freunds adjuvant alone is antiatherogenic in apoE-deficient mice and specific immunization against TNFalpha confers no additional benefit |
| Q40420842 | From the plant to chemistry--the early history of "rheumatic medication" |
| Q36438291 | Functional analysis of a human tumor necrosis factor alpha (TNF-alpha) promoter polymorphism related to joint damage in rheumatoid arthritis |
| Q39321571 | GADD45γ regulates TNF-α and IL-6 synthesis in THP-1 cells |
| Q37206996 | Gene expression profiling in the synovium identifies a predictive signature of absence of response to adalimumab therapy in rheumatoid arthritis |
| Q45885240 | Gene targeting by ribozyme against TNF-alpha mRNA inhibits autoimmune arthritis |
| Q35122176 | Gene therapy for arthritis |
| Q41702950 | Gene therapy for rheumatoid arthritis. Theoretical considerations. |
| Q34731099 | Genes and environment in arthritis: can RA be prevented? |
| Q36998001 | Genes and epigenetic processes as prospective pain targets |
| Q36580099 | Genetic analysis of innate immunity |
| Q34981859 | Genetic influences on rheumatoid arthritis in African Americans |
| Q34140190 | Genetic sphingosine kinase 1 deficiency significantly decreases synovial inflammation and joint erosions in murine TNF-alpha-induced arthritis |
| Q34526939 | Genetic studies, clinical heterogeneity, and disease outcome studies in rheumatoid arthritis |
| Q37226505 | Genome-wide association studies: a new window into immune-mediated diseases |
| Q39570156 | Granulocyte-macrophage colony-stimulating factor in Staphylococcus aureus-induced arthritis. |
| Q37498849 | Guidelines for the use of conventional and newer disease-modifying antirheumatic drugs in elderly patients with rheumatoid arthritis |
| Q33805889 | HLA polymorphisms and T cells in rheumatoid arthritis |
| Q41987472 | High production of proinflammatory and Th1 cytokines by dendritic cells from patients with rheumatoid arthritis, and down regulation upon FcgammaR triggering. |
| Q46352659 | Host modulation in rheumatoid arthritis patients with TNF blockers significantly decreases biochemical parameters in periodontitis |
| Q34731292 | How does infliximab work in rheumatoid arthritis? |
| Q38304297 | Human experimental endotoxemia in modeling the pathophysiology, genomics, and therapeutics of innate immunity in complex cardiometabolic diseases |
| Q35689463 | Human immunoglobulin G2 (IgG2) and IgG4, but not IgG1 or IgG3, protect mice against Cryptococcus neoformans infection. |
| Q35605628 | Human, viral or mutant human IL-10 expressed after local adenovirus-mediated gene transfer are equally effective in ameliorating disease pathology in a rabbit knee model of antigen-induced arthritis |
| Q74449418 | Humanization of a mouse neutralizing monoclonal antibody against tumor necrosis factor-alpha (TNF-alpha) |
| Q52602290 | Hyaluronan in immune dysregulation and autoimmune diseases. |
| Q33427482 | Hyperbaric oxygen inhibits stimulus-induced proinflammatory cytokine synthesis by human blood-derived monocyte-macrophages |
| Q36292663 | IKK{beta} as a target for treatment of inflammation induced bone loss |
| Q33716470 | IL-12 as a therapeutic target for pharmacological modulation in immune-mediated and inflammatory diseases: regulation of T helper 1/T helper 2 responses |
| Q33934436 | IL-15 drives the specific migration of CD94+ and TCR-gammadelta+ intraepithelial lymphocytes in organ cultures of treated celiac patients. |
| Q77807763 | IL-18: A TH1-inducing, proinflammatory cytokine and new member of the IL-1 family |
| Q28249632 | Identification and characterization of a pro-tumor necrosis factor-alpha-processing enzyme from the ADAM family of zinc metalloproteases |
| Q73204426 | Identification of a selectivity determinant for inhibition of tumor necrosis factor-alpha converting enzyme by comparative modeling |
| Q73097003 | Immune response to a recombinant human TNFR55-IgG1 fusion protein: auto-antibodies in rheumatoid arthritis (RA) and multiple sclerosis (MS) patients have neither neutralizing nor agonist activities |
| Q26744239 | Immunogenicity Assessment of Tumor Necrosis Factor Antagonists in the Clinical Laboratory |
| Q47380976 | Immunogenicity and loss of response to TNF inhibitors: implications for rheumatoid arthritis treatment |
| Q38080683 | Immunogenicity of anti-TNF biologic therapies for rheumatoid arthritis |
| Q40506587 | Immunological intervention reveals reciprocal roles for tumor necrosis factor-alpha and interleukin-10 in rheumatoid arthritis and systemic lupus erythematosus |
| Q41722148 | Immunological treatment of autoimmune diseases. |
| Q33760317 | Immunomodulation of autoimmune responses with monoclonal antibodies and immunoadhesins: treatment of ocular inflammatory disease in the next millennium |
| Q42643514 | Immunomodulatory effects of anti-tumor necrosis factor alpha therapy on synovium in spondylarthropathy: histologic findings in eight patients from an open-label pilot study |
| Q36484399 | Immunotherapies for Neurological Manifestations in the Context of Systemic Autoimmunity |
| Q34360546 | Immunotherapy for rheumatoid arthritis |
| Q35829575 | Importance of Kupffer cells for T-cell-dependent liver injury in mice |
| Q47685842 | Important immunoregulatory role of interleukin-11 in the inflammatory process in rheumatoid arthritis |
| Q33545943 | In vitro and in vivo effects of n-3 polyunsaturated fatty acids on human monocyte function |
| Q40661240 | In vitro and in vivo pharmacology and pharmacokinetics of a human engineered monoclonal antibody to epithelial cell adhesion molecule |
| Q71716940 | Increased incidence of neutralizing autoantibodies against interleukin-1 alpha (IL-1 alpha) in nondestructive chronic polyarthritis |
| Q35550051 | Increased peripheral T cell reactivity to microbial antigens and collagen type II in rheumatoid arthritis after treatment with soluble TNFalpha receptors |
| Q58621898 | Increased soluble p55 and p75 tumour necrosis factor-alpha receptors in patients with hepatitis C-associated mixed cryoglobulinaemia |
| Q58535949 | Induction of interleukin-6 (IL-6) autoantibodies through vaccination with an engineered IL-6 receptor antagonist |
| Q30732295 | Induction of the cyclic nucleotide phosphodiesterase PDE4B is essential for LPS-activated TNF-alpha responses |
| Q28366650 | Induction of the cytokine signal regulator SOCS3/CIS3 as a therapeutic strategy for treating inflammatory arthritis |
| Q35084908 | Infection complications associated with the use of biologic agents |
| Q35829752 | Inferences, questions and possibilities in Toll-like receptor signalling |
| Q28083759 | Inflammation induced loss of skeletal muscle |
| Q37714770 | Inflammation-sleep interface in brain disease: TNF, insulin, orexin |
| Q30307998 | Infliximab |
| Q33885648 | Infliximab (chimeric anti-tumour necrosis factor alpha monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised phase III trial. ATTRACT Study Group |
| Q48030927 | Infliximab as a treatment for recalcitrant pyoderma gangrenosum. |
| Q35591096 | Infliximab for hidradenitis suppurativa |
| Q52856626 | Infliximab for rheumatoid arthritis. |
| Q36099482 | Infliximab for the treatment of early rheumatoid arthritis |
| Q34758388 | Infliximab for the treatment of rheumatoid arthritis |
| Q50425514 | Infliximab has no apparent effect in the inner ear hearing function of patients with rheumatoid arthritis and ankylosing spondylitis |
| Q35553741 | Infliximab in spondyloarthropathy associated with Crohn's disease: an open study on the efficacy of inducing and maintaining remission of musculoskeletal and gut manifestations |
| Q24798468 | Infliximab therapy in rheumatoid arthritis and ankylosing spondylitis-induced specific antinuclear and antiphospholipid autoantibodies without autoimmune clinical manifestations: a two-year prospective study |
| Q80442663 | Infliximab treatment for ocular and extraocular manifestations of Behçet's disease |
| Q34963107 | Infliximab treatment for rheumatic disease: clinical and radiological efficacy |
| Q35553775 | Infliximab treatment for rheumatoid arthritis, with dose titration based on the Disease Activity Score: dose adjustments are common but not always sufficient to assure sustained benefit |
| Q35201036 | Infliximab treatment of rheumatoid arthritis and Crohn's disease |
| Q35070446 | Infliximab: 12 years of experience |
| Q33959133 | Infliximab: a review of its use in the management of rheumatoid arthritis |
| Q33761069 | Influence of antiTNF-alpha antibody treatment on fracture healing under chronic inflammation |
| Q41839052 | Inhibition of cartilage and bone destruction in adjuvant arthritis in the rat by a matrix metalloproteinase inhibitor |
| Q44198853 | Inhibition of cartilage destruction by double gene transfer of IL-1Ra and IL-10 involves the activin pathway |
| Q41585449 | Inhibition of interleukin-5 with a monoclonal antibody attenuates allergic inflammation |
| Q33879436 | Inhibition of transcription factors by anti-inflammatory and anti-rheumatic drugs: can variability in response be overcome? |
| Q59400563 | Inhibition of tumor necrosis factor activity minimizes target organ damage in experimental autoimmune uveoretinitis despite quantitatively normal activated T cell traffic to the retina |
| Q36334316 | Inhibition of tumor necrosis factor alpha secretion in rat Kupffer cells by siRNA: in vivo efficacy of siRNA-liposomes |
| Q41622137 | Inhibitors of tumor necrosis factor-alpha: promising agents for the treatment of multiple sclerosis? |
| Q40963970 | Innovative treatment approaches for rheumatoid arthritis. Issues in clinical trials of biological agents |
| Q36183900 | Insight into the Structural Determinants of Imidazole Scaffold-Based Derivatives as TNF-α Release Inhibitors by in Silico Explorations |
| Q35212215 | Inter-relationships between rheumatoid arthritis and periodontal disease. A review. |
| Q24793971 | Interferon-beta for treatment of rheumatoid arthritis? |
| Q36375082 | Interleukin 15 induces endothelial hyaluronan expression in vitro and promotes activated T cell extravasation through a CD44-dependent pathway in vivo |
| Q36400353 | Interleukin 6 is required for the development of collagen-induced arthritis |
| Q57232110 | Interleukin-15 mediates T cell-dependent regulation of tumor necrosis factor-α production in rheumatoid arthritis |
| Q88562718 | Interleukin-6: designing specific therapeutics for a complex cytokine |
| Q44060534 | Intra-articular IL-10 gene transfer regulates the expression of collagen-induced arthritis (CIA) in the knee and ipsilateral paw. |
| Q36120766 | Investigational anti-inflammatory agents for the treatment of ischaemic brain injury |
| Q51072387 | Ischaemic colitis in rheumatoid arthritis patients receiving tumour necrosis factor-α inhibitors: an analysis of reports to the US FDA Adverse Event Reporting System. |
| Q38156838 | Ischaemic/reperfusion injury: Role of infliximab |
| Q24799357 | JNK1 is not essential for TNF-mediated joint disease |
| Q36407354 | Juvenile idiopathic arthritis: current and future treatment options |
| Q34626968 | Juvenile rheumatoid arthritis: therapeutic perspectives |
| Q35691003 | Key feature of the catalytic cycle of TNF-alpha converting enzyme involves communication between distal protein sites and the enzyme catalytic core |
| Q37401084 | Key role of macrophages in the pathogenesis of CD18 hypomorphic murine model of psoriasis |
| Q28206018 | Lasker Clinical Medical Research Award. TNF defined as a therapeutic target for rheumatoid arthritis and other autoimmune diseases |
| Q43006478 | Life and death in the gut: more killing, less Crohn's |
| Q35110153 | Lipid peroxidation-mediated inflammation promotes cell apoptosis through activation of NF-κB pathway in rheumatoid arthritis synovial cells |
| Q45863664 | Localized expression of an anti-TNF single-chain antibody prevents development of collagen-induced arthritis |
| Q35551481 | Long term anti-tumour necrosis factor alpha monotherapy in rheumatoid arthritis: effect on radiological course and prognostic value of markers of cartilage turnover and endothelial activation. |
| Q49884213 | Long-term efficacy and safety of antitumour necrosis factor alpha treatment in rhupus: an open-label study of 15 patients |
| Q60809248 | Long-term follow-up of adalimumab monotherapy for rheumatoid arthritis in Japanese patients: a report of six cases |
| Q73117771 | Long-term follow-up of the changes in circulating cytokines, soluble cytokine receptors, and white blood cell subset counts in patients with rheumatoid arthritis (RA) after monoclonal anti-TNF alpha antibody therapy |
| Q26865649 | Lymphotoxin and TNF: how it all began-a tribute to the travelers |
| Q77788031 | Macrocyclic hydroxamate inhibitors of matrix metalloproteinases and TNF-alpha production |
| Q35859018 | Managing immunogenic responses to infliximab: treatment implications for patients with Crohn's disease |
| Q41071493 | Mast-cell-leukocyte cytokine cascades in allergic inflammation |
| Q33754764 | Matrix Metalloproteinase Gene Activation Resulting from Disordred Epigenetic Mechanisms in Rheumatoid Arthritis. |
| Q37250713 | Maturation-induces endothelial dysfunction via vascular inflammation in diabetic mice |
| Q36905584 | Mechanistic biomarkers for clinical decision making in rheumatic diseases |
| Q33793215 | Medical management of children with juvenile rheumatoid arthritis |
| Q57079507 | Methotrexate specifically modulates cytokine production by T cells and macrophages in murine collagen-induced arthritis (CIA): a mechanism for methotrexate-mediated immunosuppression |
| Q40878401 | Methotrexate use in rheumatoid arthritis |
| Q42117581 | Methotrexate: optimizing the efficacy in rheumatoid arthritis |
| Q47849220 | Modulation of angiogenic vascular endothelial growth factor by tumor necrosis factor alpha and interleukin-1 in rheumatoid arthritis |
| Q42323191 | Molecular Basis for the Neutralization of Tumor Necrosis Factor α by Certolizumab Pegol in the Treatment of Inflammatory Autoimmune Diseases |
| Q80792142 | Molecular genetics: the Emperor's clothes of drug discovery? |
| Q30480303 | Molecular interactions between T cells and fibroblast-like synoviocytes: role of membrane tumor necrosis factor-alpha on cytokine-activated T cells |
| Q35911103 | Molecular targets in immune-mediated diseases: focus on rheumatoid arthritis |
| Q35216972 | Molecular targets in immune-mediated diseases: the case of tumour necrosis factor and rheumatoid arthritis |
| Q36767393 | Molecular, biologic, and pharmacokinetic properties of monoclonal antibodies: impact of these parameters on early clinical development |
| Q36724093 | Monitoring of nonsteroidal immunosuppressive drugs in patients with lung disease and lung transplant recipients: American College of Chest Physicians evidence-based clinical practice guidelines |
| Q35026014 | Monoclonal antibodies in immune and inflammatory diseases |
| Q34236658 | Monoclonal antibody therapy |
| Q35909297 | Monoclonal antibody therapy in lymphoid leukemias |
| Q28144207 | Monoclonal antibody treatment exposes three mechanisms underlying the clinical course of multiple sclerosis |
| Q40433213 | Monoclonal anti‐TNFα Antibody as a Probe of Pathogenesis and Therapy of Rheumatoid Disease |
| Q74293321 | Mud pack therapy in osteoarthrosis. Changes in serum levels of chondrocyte markers |
| Q42765096 | Multiple sclerosis related fatigue |
| Q35651919 | Multiscale analysis of the murine intestine for modeling human diseases. |
| Q36367422 | Mutant mice without B lymphocyte follicles |
| Q35547861 | Mutual antagonism of rheumatoid arthritis and hay fever; a role for type 1/type 2 T cell balance |
| Q37229440 | Myelodysplasia and acute leukemia as late complications of marrow failure: future prospects for leukemia prevention. |
| Q40974301 | N2733, 1-[3-(3-pyridyl)-acryloyl]-2-pyrrolidinone hydrochloride inhibits LPS-induced TNF-alpha production and improves survival in endotoxemic mice |
| Q46157260 | Neutralizing IL-21 and IL-15 inhibits pro-inflammatory cytokine production in rheumatoid arthritis |
| Q33903590 | Neutrophils: molecules, functions and pathophysiological aspects |
| Q40954444 | New agents for scintigraphy in rheumatoid arthritis |
| Q41127187 | New peptide and protein drugs |
| Q33668883 | New therapeutic targets for rheumatoid arthritis |
| Q35563923 | New therapies for chronic obstructive pulmonary disease |
| Q33801264 | New vessels, new approaches: angiogenesis as a therapeutic target in musculoskeletal disorders |
| Q34585191 | Newer immunosuppressive drugs: their potential role in rheumatoid arthritis therapy |
| Q90606902 | Non-catalytic ubiquitin binding by A20 prevents psoriatic arthritis-like disease and inflammation |
| Q37650386 | Novel TNF antagonists for the treatment of rheumatoid arthritis |
| Q34504774 | Novel pro-inflammatory interleukins: potential therapeutic targets in rheumatoid arthritis |
| Q37979848 | Novel roles for the IgG Fc glycan |
| Q35040784 | Novel therapies for the treatment of juvenile rheumatoid arthritis (juvenile idiopathic arthritis). |
| Q34096275 | Novel, non-antigen-specific therapeutic approaches to autoimmune/inflammatory diseases |
| Q44404709 | On the origins of complex immune-mediated disease: the example of rheumatoid arthritis |
| Q40828764 | Opportunities for future biological therapy in SLE. |
| Q34520591 | Oral intake of Lactobacillus delbrueckii subsp. bulgaricus OLL1073R-1 prevents collagen-induced arthritis in mice |
| Q35116177 | Overview of the use of the anti-TNF agent infliximab in chronic inflammatory diseases |
| Q42276684 | Oxpentifylline inhibits tumor necrosis factor‐α mRNA transcription and protects against arthritis in mercuric chloride‐treated Brown Norway rats |
| Q33782360 | PEGylated recombinant human soluble tumour necrosis factor receptor type I (r-Hu-sTNF-RI): novel high affinity TNF receptor designed for chronic inflammatory diseases |
| Q37448240 | Paclitaxel suppresses collagen-induced arthritis: a reevaluation |
| Q37830174 | Pathogenesis of the immune reconstitution inflammatory syndrome affecting the central nervous system in patients infected with HIV. |
| Q53209315 | Pathogenetic, clinical and pharmaco-economic assessment in rheumatoid arthritis (RA). |
| Q36210063 | Payback arising from research funding: evaluation of the Arthritis Research Campaign |
| Q36309246 | Periodontitis and rheumatoid arthritis: a review. |
| Q77995177 | Peripheral blood mononuclear cells from patients with rheumatoid arthritis spontaneously secrete vascular endothelial growth factor (VEGF): specific up-regulation by tumour necrosis factor-alpha (TNF-alpha) in synovial fluid |
| Q38357886 | Pharmaceutical aspects of anti-inflammatory TNF-blocking drugs |
| Q46325862 | Pharmacogenomics of infliximab treatment using peripheral blood cells of patients with rheumatoid arthritis. |
| Q46508793 | Pharmacokinetic-Pharmacodynamic Modeling of Apratastat: A Population-Based Approach |
| Q24793076 | Phenotypic characteristics of human monocytes undergoing transendothelial migration |
| Q33964193 | Phosphodiesterase 4 inhibitors, structurally unrelated to rolipram, as promising agents for the treatment of asthma and other pathologies |
| Q64101864 | Physicochemical characterization and phase I study of CMAB008, an infliximab biosimilar produced by a different expression system |
| Q45889739 | Physiologically responsive gene therapy |
| Q24681833 | Physiology and immunology of the cholinergic antiinflammatory pathway |
| Q40977170 | Plant extracts from stinging nettle (Urtica dioica), an antirheumatic remedy, inhibit the proinflammatory transcription factor NF-kappaB. |
| Q34992787 | Polyreactivity and autoreactivity among HIV-1 antibodies |
| Q38089263 | Potential applications of designed ankyrin repeat proteins in diagnostics and therapeutics |
| Q35761447 | Prediction of antitumour necrosis factor clinical efficacy by real-time visualisation of apoptosis in patients with Crohn's disease |
| Q38820248 | Prevalence, incidence and prognosis of chronic kidney disease classified according to current guidelines: a large retrospective cohort study of rheumatoid arthritis patients |
| Q74339945 | Prevention of collagen-induced arthritis in DBA/1 mice by oral administration of AZ-9, a bacterial polysaccharide from Klebsiella oxytoca |
| Q40861531 | Pro- and anti-inflammatory cytokines in rheumatoid arthritis |
| Q36243974 | Pro-inflammatory cytokines in rheumatoid arthritis: pathogenetic and therapeutic aspects |
| Q78087045 | Proceedings of a symposium on "Immunosenescence--A major cause of disease in the elderly: from molecules to patients": summary |
| Q74384503 | Production of cytokines, vascular endothelial growth factor, matrix metalloproteinases, and tissue inhibitor of metalloproteinases 1 by tenosynovium demonstrates its potential for tendon destruction in rheumatoid arthritis |
| Q32103173 | Production of human monoclonal antibodies in SCID mouse |
| Q42943792 | Production of nitric oxide in the synovial membrane of rheumatoid and osteoarthritis patients |
| Q33731344 | Production of recombinant subunit vaccines: protein immunogens, live delivery systems and nucleic acid vaccines |
| Q34526927 | Prognostic use of human leukocyte antigen genotyping for rheumatoid arthritis susceptibility, disease course, and clinical stratification |
| Q54107468 | Proinflammatory cytokines and treatment of disease. |
| Q47718177 | Pronounced diversity in electronic and chemical properties between the catalytic zinc sites of tumor necrosis factor-alpha-converting enzyme and matrix metalloproteinases despite their high structural similarity |
| Q35619546 | Prospects for Therapeutic Targeting of MicroRNAs in Human Immunological Diseases |
| Q40968027 | Prospects of immunotherapy for rheumatoid arthritis |
| Q78171066 | Prospects of new therapeutic approaches for Crohn's disease |
| Q43087132 | Proteolytic release of membrane bound intercellular regulators |
| Q35843827 | Psoriasis: immunopathogenesis and evolving immunomodulators and systemic therapies; U.S. experiences |
| Q42537156 | Pyrroles and other heterocycles as inhibitors of p38 kinase |
| Q56765531 | RETRACTED: Infliximab in patients with primary Sjögren's syndrome: a pilot study |
| Q73107122 | Randomised controlled trial of CDP571 antibody to tumour necrosis factor-alpha in Crohn's disease |
| Q49049736 | Randomized double-blind comparison of chimeric monoclonal antibody to tumor necrosis factor alpha (infliximab) versus placebo in active spondylarthropathy |
| Q53992563 | Randomized, double-blind trial of anti-interferon-gamma antibodies in rheumatoid arthritis. |
| Q77549337 | Reactivation of histoplasmosis after treatment with infliximab |
| Q33964547 | Recent advances in the genetics of systemic lupus erythematosus |
| Q37275412 | Recent advances in the treatment of eosinophilic esophagitis |
| Q33847017 | Recent advances in the treatment of rheumatoid arthritis |
| Q41878593 | Regression of macular edema secondary to branch retinal vein occlusion during anti-TNF-alpha therapy for rheumatoid arthritis |
| Q33873657 | Regulation of IFN response gene activity during infliximab treatment in rheumatoid arthritis is associated with clinical response to treatment |
| Q73521731 | Regulation of angiogenesis by the C-X-C chemokines interleukin-8 and epithelial neutrophil activating peptide 78 in the rheumatoid joint |
| Q34830660 | Regulation of cytokine signaling and inflammation |
| Q42067802 | Regulation of tumour necrosis factor production by adrenal hormones in vivo: insights into the antiinflammatory activity of rolipram |
| Q53630006 | Rehabilitation or the death penalty: autoimmune B cells in the dock. |
| Q92798584 | Remicade® (infliximab): 20 years of contributions to science and medicine |
| Q35083436 | Repair of local bone erosions and reversal of systemic bone loss upon therapy with anti-tumor necrosis factor in combination with osteoprotegerin or parathyroid hormone in tumor necrosis factor-mediated arthritis |
| Q35551412 | Repeated infusions of infliximab, a chimeric anti-TNFalpha monoclonal antibody, in patients with active spondyloarthropathy: one year follow up |
| Q42694138 | Repeated therapy with monoclonal antibody to tumour necrosis factor alpha (cA2) in patients with rheumatoid arthritis |
| Q57536905 | Research in complex diseases |
| Q26822029 | Review article: dermatological complications of immunosuppressive and anti-TNF therapy in inflammatory bowel disease |
| Q37979135 | Reviewing concepts in the immunopathogenesis of psoriasis |
| Q36324975 | Rheumatic diseases: the effects of inflammation on bone |
| Q57349151 | Rheumatoid arthritis |
| Q71046923 | Rheumatoid arthritis |
| Q74541001 | Rheumatoid arthritis |
| Q87726283 | Rheumatoid arthritis |
| Q43204160 | Rheumatoid arthritis in Latin America. Important challenges to be solved. |
| Q37294842 | Rheumatoid arthritis synovial fibroblasts produce a soluble form of the interleukin-7 receptor in response to pro-inflammatory cytokines |
| Q38357554 | Rheumatoid arthritis therapy reappraisal: strategies, opportunities and challenges |
| Q34275998 | Rheumatoid arthritis. From bench to bedside |
| Q34706975 | Rheumatoid arthritis: developing pharmacological therapies |
| Q40383687 | Risk of Nonmelanoma Skin Cancer Associated With the Use of Immunosuppressant and Biologic Agents in Patients With a History of Autoimmune Disease and Nonmelanoma Skin Cancer |
| Q82835713 | Risk of lymphoma in patients receiving antitumor necrosis factor therapy: a meta-analysis of published randomized controlled studies |
| Q77627732 | Role of pro-inflammatory cytokines in rheumatoid arthritis |
| Q74242486 | Role of tumor necrosis factor alpha and potential benefit of tumor necrosis factor blockade treatment in systemic lupus erythematosus: comment on the editorial by Pisetsky |
| Q38541995 | Roles of A20 in autoimmune diseases |
| Q56452759 | STAT4 but not TRAF1/C5 variants influence the risk of developing rheumatoid arthritis and systemic lupus erythematosus in Colombians |
| Q34595156 | Safety and efficacy of disease-modifying anti-rheumatic agents: focus on the benefits and risks of etanercept |
| Q35194346 | Safety and efficacy of disease-modifying antirheumatic agents in rheumatoid arthritis and juvenile rheumatoid arthritis |
| Q46545377 | Safety and tolerability of infliximab therapy: suggestions and criticisms based on wide clinical experience |
| Q26798209 | Scanning for Therapeutic Targets within the Cytokine Network of Idiopathic Inflammatory Myopathies |
| Q78177021 | Searching for the needle in the haystack: another candidate needle in autoimmune hepatitis? |
| Q41546325 | Seeing the wood for the trees: the forgotten role of neutrophils in rheumatoid arthritis |
| Q38755912 | Selected cytokine pathways in rheumatoid arthritis |
| Q47913427 | Selective elimination of synovial inflammatory macrophages in rheumatoid arthritis by an Fcγ receptor I–directed immunotoxin |
| Q35937819 | Serious infections associated with anticytokine therapies in the rheumatic diseases |
| Q40969473 | Serum Zinc Concentration and C-Reactive Protein in Individuals with Human Immunodeficiency Virus Infection: the Positive Living with HIV (POLH) Study |
| Q24804764 | Serum cartilage oligomeric matrix protein (COMP) decreases in rheumatoid arthritis patients treated with infliximab or etanercept |
| Q33578865 | Serum p55 and p75 tumour necrosis factor receptors as markers of disease activity in juvenile chronic arthritis |
| Q43870766 | Sexual dimorphism in innate immunity |
| Q42453486 | Shikonins, phytocompounds from Lithospermum erythrorhizon, inhibit the transcriptional activation of human tumor necrosis factor alpha promoter in vivo |
| Q33872866 | Single nucleotide polymorphisms at the TRAF1/C5 locus are associated with rheumatoid arthritis in a Han Chinese population |
| Q77118243 | Soluble tumor necrosis factor receptor (p75) fusion protein (ENBREL) as a therapy for rheumatoid arthritis |
| Q41471156 | Specific drugs for a complex disease: can there be a magic bullet against rheumatoid arthritis? |
| Q44585210 | Spironolactone inhibits production of proinflammatory cytokines, including tumour necrosis factor-alpha and interferon-gamma, and has potential in the treatment of arthritis |
| Q81037844 | Statins and rheumatoid arthritis |
| Q52362617 | Structural Biology of the TNFα Antagonists Used in the Treatment of Rheumatoid Arthritis. |
| Q41355406 | Structural features and biochemical properties of TNF-alpha converting enzyme (TACE). |
| Q91163336 | Structure-Based Design, Synthesis, and Biological Evaluation of Imidazo[4,5-b]Pyridin-2-one-Based p38 MAP Kinase Inhibitors: Part 2 |
| Q92841691 | Structure-Based Design, Synthesis, and Biological Evaluation of Imidazo[4,5-b]pyridin-2-one-Based p38 MAP Kinase Inhibitors: Part 1 |
| Q32068329 | Structure-activity relationships of quinazoline derivatives: dual-acting compounds with inhibitory activities toward both TNF-alpha production and T cell proliferation |
| Q34731209 | Studies of T-cell activation in chronic inflammation |
| Q33782349 | Summary of clinical trials in rheumatoid arthritis using infliximab, an anti-TNFalpha treatment |
| Q45864343 | Suppressed severity of collagen-induced arthritis by in vivo transfection of nuclear factor kappaB decoy oligodeoxynucleotides as a gene therapy |
| Q47859509 | Suppression of chronic inflammation with engineered nanomaterials delivering nuclear factor κB transcription factor decoy oligodeoxynucleotides |
| Q45869248 | Sustained secretion of anti-tumor necrosis factor α monoclonal antibody from ex vivo genetically engineered dermal tissue demonstrates therapeutic activity in mouse model of rheumatoid arthritis |
| Q46846959 | Switching the therapy from etanercept to infliximab in a child with rheumatoid factor positive polyarticular juvenile idiopathic arthritis |
| Q35551058 | Synovial macrophage-osteoclast differentiation in inflammatory arthritis |
| Q74452151 | Synthesis and bioactivities of novel bicyclic thiophenes and 4,5,6,7-tetrahydrothieno[2,3-c]pyridines as inhibitors of tumor necrosis factor-alpha (TNF-alpha) production |
| Q73980258 | Synthesis and bioactivities of novel piperidylpyrimidine derivatives: inhibitors of tumor necrosis factor-alpha production |
| Q21134808 | Systematic review and meta-analysis of the efficacy and safety of existing TNF blocking agents in treatment of rheumatoid arthritis |
| Q35553078 | Systematic safety follow up in a cohort of 107 patients with spondyloarthropathy treated with infliximab: a new perspective on the role of host defence in the pathogenesis of the disease? |
| Q36452687 | T-cell activation via CD26 and caveolin-1 in rheumatoid synovium |
| Q43837384 | TIA-1 regulates the production of tumor necrosis factor alpha in macrophages, but not in lymphocytes |
| Q40374598 | TNF alpha is an effective therapeutic target for rheumatoid arthritis |
| Q38797655 | TNF autovaccination induces self anti-TNF antibodies and inhibits metastasis in a murine melanoma model |
| Q34240744 | TNF blockade in the treatment of rheumatoid arthritis: infliximab versus etanercept |
| Q41678435 | TNF inhibitors are produced spontaneously by rheumatoid and osteoarthritic synovial joint cell cultures: evidence of feedback control of TNF action. |
| Q57351466 | TNF-alpha Dominates Cytokine mRNA Expression in Lymphoid Tissues of Rats Developing Collagen- and Oil-Induced Arthritis |
| Q73027768 | TNF-alpha-mediated expression of membrane-type matrix metalloproteinase in rheumatoid synovial fibroblasts |
| Q37562070 | TNF-α gene silencing using polymerized siRNA/thiolated glycol chitosan nanoparticles for rheumatoid arthritis |
| Q54438066 | TNFRI is a positive T-cell costimulatory molecule important for the timing of cytokine responses. |
| Q35540023 | TNFalpha kinoid vaccination-induced neutralizing antibodies to TNFalpha protect mice from autologous TNFalpha-driven chronic and acute inflammation |
| Q50233826 | TNFα depleting therapy improves fertility and animal welfare in TNFα-driven transgenic models of polyarthritis when administered in their routine breeding |
| Q24657292 | TRAF1-C5 as a risk locus for rheumatoid arthritis--a genomewide study |
| Q28140568 | Tachykinin receptors on human monocytes: their involvement in rheumatoid arthritis |
| Q41632994 | Taming TNF: strategies to restrain this proinflammatory cytokine |
| Q37229283 | Target effector role of vascular endothelium in the inflammatory response: insights from the clinical trial of anti-TNF alpha antibody in rheumatoid arthritis |
| Q38160905 | Targeting TNF-α for the treatment of inflammatory bowel disease |
| Q26853270 | Targeting novel peripheral mediators for the treatment of chronic pain |
| Q57470500 | Targeting the extracellular matrix for delivery of bioactive molecules to sites of arthritis |
| Q34436456 | Targeting tumor necrosis factor alpha. New drugs used to modulate inflammatory diseases |
| Q41679275 | Techniques to investigate cellular and molecular interactions in the host response to implanted biomaterials. |
| Q73128904 | Thalidomide analogue CC1069 inhibits development of rat adjuvant arthritis |
| Q43704395 | The Fas-FasL death receptor and PI3K pathways independently regulate monocyte homeostasis |
| Q36286414 | The Therapeutic Potential for PI3K Inhibitors in Autoimmune Rheumatic Diseases |
| Q41978298 | The anti-inflammatory actions of methotrexate are critically dependent upon the production of reactive oxygen species |
| Q54380161 | The association between TNFα gene polymorphisms and susceptibility to rheumatoid arthritis in an ethnic Kashmiri population: relationship with disease activity and severity markers. |
| Q40938782 | The basis of current and future therapy for inflammatory bowel disease |
| Q35556360 | The biology of TNF blockade |
| Q24812699 | The contact-mediated response of peripheral-blood monocytes to preactivated T cells is suppressed by serum factors in rheumatoid arthritis |
| Q45869577 | The contralateral effect conferred by intra-articular adenovirus-mediated gene transfer of viral IL-10 is specific to the immunizing antigen |
| Q41265044 | The cytokine network in rheumatoid arthritis: definition of TNF alpha as a therapeutic target |
| Q35067114 | The cytokine network in sarcoidosis and its clinical relevance |
| Q38040749 | The dual roles of inflammatory cytokines and chemokines in the regulation of autoimmune diseases and their clinical implications |
| Q36373315 | The effect of TNFalpha blockade on the antinuclear antibody profile in patients with chronic arthritis: biological and clinical implications |
| Q46088038 | The effect of anti-TNF-α vs. DMARDs on fatigue in rheumatoid arthritis patients |
| Q36204163 | The efficacy of anti-TNF in rheumatoid arthritis, a comparison between randomised controlled trials and clinical practice |
| Q40859444 | The future role of anti-tumour necrosis factor (TNF) products in the treatment of rheumatoid arthritis |
| Q34108788 | The genetics of rheumatoid arthritis: influences on susceptibility, severity, and treatment response |
| Q34504770 | The histone deacetylase inhibitor ITF2357 reduces production of pro-inflammatory cytokines in vitro and systemic inflammation in vivo |
| Q34745790 | The immunology of inflammatory bowel disease |
| Q81256806 | The long-term effect of anti TNF-alpha treatment on temporomandibular joints, oral mucosa, and salivary flow in patients with active rheumatoid arthritis: a pilot study |
| Q41558341 | The mechanisms of action of disease-modifying antirheumatic drugs: a review with emphasis on macrophage signal transduction and the induction of proinflammatory cytokines |
| Q33867213 | The meteorology of cytokine storms, and the clinical usefulness of this knowledge |
| Q34122715 | The pathogenesis and prevention of joint damage in rheumatoid arthritis: advances from synovial biopsy and tissue analysis |
| Q48029200 | The pathogenesis of rheumatoid arthritis: new insights from old clinical data? |
| Q41276467 | The potential biological and clinical significance of the soluble tumor necrosis factor receptors |
| Q33527432 | The protective antibodies induced by a novel epitope of human TNF-alpha could suppress the development of collagen-induced arthritis |
| Q33782321 | The rationale for the current boom in anti-TNFalpha treatment. Is there an effective means to define therapeutic targets for drugs that provide all the benefits of anti-TNFalpha and minimise hazards? |
| Q33372271 | The relationship between heart rate variability and inflammatory markers in cardiovascular diseases |
| Q34677503 | The representation of inflammatory signals in the brain - a model for subjective fatigue in multiple sclerosis |
| Q24799403 | The role and clinical implications of G6PI in experimental models of rheumatoid arthritis |
| Q41170697 | The role of cytokines in rheumatoid arthritis. The Croonian Lecture 1995. |
| Q41228313 | The role of macrophages in chronic arthritis |
| Q36823753 | The role of tumor necrosis factor-alpha (TNF-alpha) in bone resorption present in middle ear cholesteatoma |
| Q37784863 | The roles of TNF in brain dysfunction and disease |
| Q34654538 | The saga of the discovery of IL-1 and TNF and their specific inhibitors in the pathogenesis and treatment of rheumatoid arthritis |
| Q55449629 | The science of rheumatoid arthritis: a prelude. |
| Q24805297 | The stressed synovium |
| Q39781830 | The tetracycline derivative minocycline differentially affects cytokine production by monocytes and T lymphocytes |
| Q35164732 | The therapeutic potential of TNF-alpha blockade in rheumatoid arthritis |
| Q35859217 | The treatment of rheumatoid arthritis |
| Q34108762 | The treatment of rheumatoid arthritis: a review of recent clinical trials |
| Q96229604 | The trimer to monomer transition of Tumor Necrosis Factor-Alpha is a dynamic process that is significantly altered by therapeutic antibodies |
| Q41233084 | The use of SCID mice in biotechnology and as a model for human disease |
| Q35688168 | The use of TNF-alpha blocking agents in rheumatoid arthritis: an overview |
| Q36916918 | The use of TNF-alpha blocking agents in rheumatoid arthritis: an update |
| Q41465945 | The use of biologics in the treatment of rheumatoid arthritis (RA)--the good news and the bad news |
| Q33554356 | The use of tumour necrosis factor alpha-blockers in daily routine. An Austrian consensus project |
| Q41038790 | Therapeutic TNF Inhibitors can Differentially Stabilize Trimeric TNF by Inhibiting Monomer Exchange |
| Q56896528 | Therapeutic antibody fragments with prolonged in vivo half-lives |
| Q48825054 | Therapeutic antibody targeting of indoleamine-2,3-dioxygenase (IDO2) inhibits autoimmune arthritis |
| Q39210558 | Therapeutic approaches for the delivery of TNF-α siRNA. |
| Q56344227 | Therapeutic implications of how TNF links APOE, P-tau, α-synuclein, β-amyloid, and insulin resistance in neurodegenerative diseases |
| Q28137808 | Therapeutic monoclonal antibodies |
| Q35140855 | Therapeutic strategies for rheumatoid arthritis |
| Q36490256 | Therapeutic targeting of the inflammome |
| Q24806367 | Therapy of ankylosing spondylitis and other spondyloarthritides: established medical treatment, anti-TNF-alpha therapy and other novel approaches |
| Q77627754 | Therapy of rheumatoid arthritis by blocking IL-6 signal transduction with a humanized anti-IL-6 receptor antibody |
| Q34108776 | Therapy of rheumatoid arthritis: new developments and trends |
| Q34731092 | Therapy of systemic lupus erythematosus: a look into the future |
| Q37682799 | Tocilizumab in the treatment of rheumatoid arthritis and beyond |
| Q53614685 | Toll-like receptors: a new target in rheumatoid arthritis? |
| Q58259640 | Transgenic Models for Arthritis: Useful Clues to Be Gained? |
| Q34567932 | Treating rheumatoid arthritis with new disease modifying drugs |
| Q42775955 | Treating rheumatoid arthritis with tumour necrosis factor alpha blockade |
| Q73502940 | Treatment of Rheumatoid Arthritis with a Recombinant Human Tumor Necrosis Factor Receptor (p75)–Fc Fusion Protein |
| Q53983532 | Treatment of experimental autoimmune myasthenia gravis with recombinant human tumor necrosis factor receptor Fc protein. |
| Q33358541 | Treatment of refractory psoriatic arthritis with infliximab: a 12 month observational study of 16 patients |
| Q36300479 | Treatment of rheumatoid arthritis by molecular-targeted agents: efficacy and limitations |
| Q45153959 | Treatment of rheumatoid arthritis in the third millennium |
| Q47163453 | Treatment of rheumatoid arthritis with biological agents - as a typical and common immune-mediated inflammatory disease. |
| Q33618096 | Treatment of ulcerative colitis in the cottontop tamarin using antibody to tumour necrosis factor alpha |
| Q33946522 | Treatment options for rheumatoid arthritis: celecoxib, leflunomide, etanercept, and infliximab |
| Q61863535 | Treatment with monoclonal anti-tumor necrosis factor alpha antibody results in an accumulation of Th1 CD4+ T cells in the peripheral blood of patients with rheumatoid arthritis |
| Q40845949 | Triple therapy with methotrexate, sulfasalazine, and hydroxychloroquine in patients with rheumatoid arthritis |
| Q44798829 | Tumor necrosis factor alpha blockade with infliximab for refractory uveitis and scleritis |
| Q33328963 | Tumor necrosis factor alpha drugs in rheumatoid arthritis: systematic review and metaanalysis of efficacy and safety |
| Q33786546 | Tumor necrosis factor alpha gene regulation: enhancement of C/EBPbeta-induced activation by c-Jun |
| Q73691790 | Tumor necrosis factor blockade in actively induced experimental autoimmune encephalomyelitis prevents clinical disease despite activated T cell infiltration to the central nervous system |
| Q38259127 | Tumor necrosis factor inhibitors: clinical utility in autoimmune diseases |
| Q77362495 | Tumor necrosis factor locus: genetic organisation and biological implications |
| Q71612538 | Tumor necrosis factor priming of peripheral blood neutrophils from rheumatoid arthritis patients |
| Q43845628 | Tumor necrosis factor receptor p55 and p75 deficiency protects mice from developing experimental autoimmune myasthenia gravis |
| Q34276023 | Tumor necrosis factor-alpha blockade in the treatment of rheumatoid arthritis |
| Q40975748 | Tumoricidal activity of tumor necrosis factor-related apoptosis-inducing ligand in vivo. |
| Q77299281 | Tumour necrosis factor (TNF) gene polymorphism influences TNF-alpha production in lipopolysaccharide (LPS)-stimulated whole blood cell culture in healthy humans |
| Q57079509 | Tumour necrosis factor (TNF) production by T cell receptor-primed T lymphocytes is a target for low dose methotrexate in rheumatoid arthritis |
| Q33611149 | Tumour necrosis factor alpha and mucocutaneous leishmaniasis |
| Q41491900 | Tumour necrosis factor and Crohn's disease |
| Q61819217 | Tumour necrosis factor and cancer |
| Q34406958 | Tumour necrosis factor and lymphotoxin: molecular aspects and role in tissue-specific autoimmunity |
| Q37808889 | Tumour necrosis factor antagonists and the risk of cardiovascular disease in patients with rheumatoid arthritis: a systematic literature review |
| Q34127393 | Tumour necrosis factor in chronic heart failure: a peripheral view on pathogenesis, clinical manifestations and therapeutic implications |
| Q35989499 | Tumour necrosis factor inhibitors: risks and benefits in patients with rheumatoid arthritis |
| Q57569294 | Tumour necrosis factor α and interleukin 1β in relapse of Crohn's disease |
| Q34181975 | Tumour necrosis factor-alpha blockade: a new era for effective management of rheumatoid arthritis |
| Q44258496 | Tumour necrosis factor-alpha induces ectopic activity in nociceptive primary afferent fibres |
| Q34192914 | Tumour necrosis factor-alpha: the role of this multifunctional cytokine in asthma |
| Q36094915 | Tumour necrosis factor-α inhibition can stabilize disease in progressive vitiligo. |
| Q37120830 | Two independent alleles at 6q23 associated with risk of rheumatoid arthritis |
| Q73034244 | Unconventional T-cell activation by IL-15 in rheumatoid arthritis |
| Q33753656 | Unimpaired autoreactive T-cell traffic within the central nervous system during tumor necrosis factor receptor-mediated inhibition of experimental autoimmune encephalomyelitis |
| Q39164941 | Update on biosimilars in rheumatology |
| Q34962946 | Updated consensus statement on biological agents for the treatment of rheumatoid arthritis and other rheumatic diseases (May 2002). |
| Q34560553 | Updated consensus statement on tumour necrosis factor blocking agents for the treatment of rheumatoid arthritis and other rheumatic diseases (April 2001) |
| Q61953724 | VISUALising a new framework for the treatment of uveitis |
| Q44599587 | Value of anti-TNF-alpha molecules in inflammatory and infectious diseases |
| Q33642739 | Vasculitic peripheral ulcerative keratitis |
| Q89399148 | Verification between Original and Biosimilar Therapeutic Antibody Infliximab Using nSMOL Coupled LC-MS Bioanalysis in Human Serum |
| Q58691977 | What Have We Learned about the Pathogenesis of Rheumatoid Arthritis from TNF-Targeted Therapy? |
| Q37842638 | What can the periodontal community learn from the pathophysiology of rheumatoid arthritis? |
| Q30826279 | What is the utility of routine ANA testing in predicting development of biological DMARD-induced lupus and vasculitis in patients with rheumatoid arthritis? Data from a single-centre cohort |
| Q24792345 | Where is biological therapy going? |
| Q44973883 | Zoledronic acid protects against local and systemic bone loss in tumor necrosis factor-mediated arthritis |
| Q73182174 | [Anti-TNF-alpha monoclonal antibodies in the treatment of rheumatoid arthritis] |
| Q52884662 | [Anticytokine therapy]. |
| Q53855814 | [Biologicals in treatment of rheumatoid arthritis and other inflammatory arthropathies]. |
| Q80126732 | [Biologicals: a new therapeutic approach for inflammatory diseases] |
| Q64905539 | [Biologics in Rhinology - Forthcoming Personalized Concepts: the Future Starts Today]. |
| Q87792267 | [Biologics] |
| Q81288165 | [Modern antirheumatic pharmacotherapy. Low molecular weight substances vs. biologicals] |
| Q73697023 | [Pathogenesis of rheumatoid arthritis] |
| Q53610953 | [Pathogenic cells of rheumatic inflammation as the target of modern therapies]. |
| Q73370072 | [Rheumatoid arthritis: new molecular and cellular aspects] |
| Q74042917 | [Systematic review of clinical trials on the treatment of rheumatoid arthritis with tumour necrosis factor alpha inhibitors] |
| Q84373485 | [Treatment of patients with destructive arthritis with certolizumab pegol] |
| Q73164408 | [Update of rheumatology--II. State and prospectives of chemotherapy in chronic arthritis] |
| Q36098311 | cDNA phage display for the discovery of theranostic autoantibodies in rheumatoid arthritis. |
Search more.